PharMEDium Services, LLC, Lake Forest, IL
Is PharMEDium Services, LLC registered with the FDA as a 503B outsourcing facility?
No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels it a 503A facility.
Does PharMEDium Services, LLC hold a Illinois pharmacy license?
No license with this exact name and city was found in the Illinois Department of Financial and Professional Regulation file dated Nov 13, 2026. A pharmacy can hold its license under a different legal name, so this is not a finding that it is unlicensed.
Has PharMEDium Services, LLC had a state board action or FDA letter?
FDA letters: no matching record found on FDA’s compounding inspections and actions page (current as of Oct 22, 2026, covering 2019 on) on Nov 15, 2026; the page lists 1 other action for PharMEDium Services, LLC. State board actions: no Illinois Department of Financial and Professional Regulation action under this exact name and city was found in the board’s license dataset (actions dated May 23, 1980 to Sep 10, 2026) on Nov 13, 2026.
FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.
- Names in FDA records
- PharMEDium Services, LLC
- Location
- Lake Forest, IL
- Type as FDA labels it
- 503A
- FDA 503B list
- No matching record found
- Form 483s on FDA’s actions page
- 0
- Warning letters on FDA’s actions page
- 0
- Latest action on that page
- May 22, 2019
- FDA Data Dashboard inspections
- 2 inspections: 2 OAI; 2 published Form 483s
- Form 483 text on this page
- 2 Form 483s, 12 observations
- State board records
- No exact match
FDA inspections and letters
FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as PharMEDium Services, LLC, a 503A facility, with 1 dated action.
| Document | |||
|---|---|---|---|
| May 22, 2019 | Press release or statement | FDA Press Release : Federal Judge Enters Consent Decree Against Compounder PharMedium Services for Violations at Multiple Facilities (5/22/2019) | FDA copy (archived) |
FDA inspection classifications and published Form 483s
The FDA Data Dashboard, read Nov 15, 2026, lists Pharmedium Services, LLC, Lake Forest, IL (FEI number 3005051736), matched to this page by exact name, city and state. It lists 2 inspections: 2 OAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.
| Inspection ended | Classification | Project area and product type | FEI | Inspection ID |
|---|---|---|---|---|
| Apr 11, 2018 | Official Action Indicated (OAI) | Drug Quality Assurance (Drugs) | 3005051736 | 1047678 |
| Jan 4, 2016 | Official Action Indicated (OAI) | Drug Quality Assurance (Drugs) | 3005051736 | 956397 |
Form 483s FDA has published for this site
- May 9, 2018: Form 483 to Pharmedium Services, LLC, published Jan 17, 2024. fda.gov
- Apr 18, 2016: Form 483 to Pharmedium Services, LLC, published Jan 17, 2024. fda.gov
FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.
Form 483 observations
A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.
FDA’s published Form 483s for this site have 12 numbered observations in all, across 2 inspections ending Jan 4, 2016 to Apr 11, 2018. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.
Inspection Apr 11, 2018: 6 observations
- Firm on the cover
- , 150 N Field Dr St e 350 Pharmedium Services, LLC, Lake Forest, IL 60045- 2506
- FEI number
- 3005051736
- Establishment type on the cover
- Out sourcing Facilit y Headquart ers
- FDA district office on the cover
- 550 W. Jackson Blvd., Suit e 1500 Chicago, I L 60661- 4716
- Matched to this page by
- FEI number on the cover; linked from Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
This 483 is a scanned image. The text below is the PDF’s own text layer, which can misread characters; the PDF is the record.
Observation 1
Procedures are not established which are designed to assure that the responsible officials of the fnm, if they are not personally involved in or immediately aware of such actions, are notified in writing of investigations conducted.
Specifically,
Per CPS-086, the Corporate VP of Quality is "responsible for all product dispositions associated with failure investigations" and the "administration of Quality programs to include: Nonconformance (NCR's ), Out of Specifications (OOS), CoIlective Action/Preventative Action (CAPA) and complaints".
Examples of product failures missing Co1porate Quality Unit notification:
1. Investigation 17TN927 was initiated on 06/01/2017 as a suspected "sterility failure".
2. CNC-17-401 was reported on 10/26/2017 as a confirmed OOS for "failed endotoxin".
3. CNC-17-472 was reported on 12/0712017 as a confirmed OOS for "failed endotoxin".
Your firm has failed to provide documentation to ensure the Corporate Quality Unit was routinely informed and procedures followed from 01-01-2017 to 01/03/2018, of any ongoing product safety concerns generated as a NCR or OOS investigation.
Observation 2
The responsibilities and procedures applicable to the quality control unit are not fully followed. Electronic records are used, but they do not meet requirements to ensure that they are trustworthy, reliable and generally equivalent to paper records.
Specifically,
The Corporate Quality/Compliance Unit has failed to follow written procedures, vital to maintaining overall Corporate Quality/Compliance oversight of your production facilities from 01/01/2017 to 01/03/2018.
Per CPS-086, "Quality Unit Responsibility" is directly assigned to the VP of Quality, Co1porate HQ, Lake Forest, IL. This position is responsible for "all product dispositions associated with failure investigations" & "for the appropriate elevation to Co1porate Management of any critical quality events".
Additionally, CPS-80 establishes that, at least[(b) 4) IC01porate Management is to attend a "Compliance Review/Management Review" to: "ensure that the quality system and subsystems are effectively established, implemented and maintained at all levels".
Review of this Quality System attribute found:
1. <Redacted B4> Compliance/Management Review was not conducted.
2. ...
Observation 3
Written records of investigations into unexplained discrepancies do not include the conclusions and follow-up.
Specifically,
Your firm has approximately 630 confirmed OOS's with associated investigations and no conclusion or follow up.
For example:
CNC-17-366 (0.2mg/ml Hydromorphone and 1 mg/ml Hydromorphone), reported on 10/12/2017 is approximately 157 days past due.
MNC-17-2012 (1 Omcg/mL Fentanyl Citrate), reported on 12/06/2017 is approximately 90 days past due.
CNC-18-064 (0.2 mg/ml Hydromorphone), reported on 02/13/2018 is approximately 30 days past due.
MNC-17-2013 (Fentanyl Citrate/Bupivacaine), reported on 12/06/2017 is approximately 90 days past due.
Review of each facility and year the OOS was initiated demonstrates:
Memphis:
2017: approximately 267 open OOS's that are 420-60 days without resolution.
2018: approximately 51 open OOS's that are 90-30 days without resolution.
Cleveland, MS:
2017: approximately 47 open OOS's that are 165-70 days without resolution.
2018: approximately 31 open OOS 's that are 78-30 days without resolution.
Sugar Land, TX:
2017: approximately 187 open OOS's that are 420-120 days without resolution. ...
Observation 4
Batch production and control records do not include the results of any investigation made into any unexplained discrepancy, whether or not the batch of diug product had ah eady been distributed. Electronic records are used, but they do not meet requirements to ensure that they are trnstworthy, reliable and generally equivalent to paper records.
Specifically,
A) Lot/batch numbers: 170320090S, 170320098S, 172120168S & 1 72280034S produced at your Sugar L and, TX facility all failed sterility testing.
Review of the following batch records demonstrated:
170320090S (0.2% Ropivacaine HCL in 0.9% Sodium Chloride Injection) batch record is incomplete.
1) F-728-4a has not been completed; the Investigation #/NCR# associated with a confirmed OOS has not been indicated. Form has not been signed as having been reviewed or is missing.
2) F-728-Sc has not been completed or reviewed.
3) F-792-001 has been partially completed indicating a failed sterility test.
4) F-611-002 (Quarantine Report) is missing.
170320098S (0.2% Ropivacaine HCL in 0.9% Sodium Chloride Injection) batch record is incomplete. ...
Observation 5
Suitable reader or photocopying equipment was not made readily available for drug product records maintained using reduction techniques. Electronic records are used, but they do not meet systems validation requirements to ensure that they are trustworthy, reliable and generally equivalent to paper records.
Specifically,
The Corporate Quality Unit has been aware of and approved the use of <Redacted B4> document storage system provided by <Redacted B4> for the storage of production records since at least 08/2017 at all production facilities. There are currently no standardized operating procedures for its use. There is no indication this system has been validated and no documentation was provided to establish said validation, Per CPS-017. Use of this system during the establishment of formal procedures for its use is ongoing.
Furthermore, much of the documentation <Redacted B4> forms used by your firm are currently in a Word File format, utilizing a combination of data entry, hand writing or both. Such modalities could subject your records to potential manipulation. Regular audit trails are not conducted on any system.
Observation 6
Individuals responsible for supervising the manufacture and processing of a drug product lack the training to perform their assigned functions in such a manner as to assure the drug product has the safety, identity, strength, quality and purity that it prompts or is represented to possess.
Specifically,
Your firm's training program qualification is not fully established.
Per CPS-0003 "New Course Design and Training Implementation Model", Trainers are to have had training provided by <Redacted B4> to conduct <Redacted B4> training. <Redacted B4> has been identified as having provided any such Aseptic Processing training to <Redacted B4>
Inspection Nov 17, 2015 to Jan 4, 2016: 6 observations
- Firm on the cover
- Pharmedium Services, LLC, 150 N Field Dr Ste 350, Lake Forest, IL 60045-2506
- FEI number
- 3005051736
- Establishment type on the cover
- Outsourcing Facility Headquarters
- FDA district office on the cover
- 550 W. Jackson Blvd., Suite 1500 Chicago, IL 60661-4716
- Matched to this page by
- FEI number on the cover; linked from Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
This 483 is a scanned image. The text below is the PDF’s own text layer, which can misread characters; the PDF is the record.
Observation 1
Drug product containers or closures are reactive so as to alter the safety, identity, strength, quality, and purity of the drug beyond the official or established requirements. Specifically, your firm failed to identify that REDACTED (B)(4) resulted in the container no longer meeting the characteristics evaluated during initial stability testing for each of your applicable finished drug products. As a result, your firm formulated finished drug products into container/closures REDACTED (B)(4) and approved the release of multiple batches from different drug products that subsequently failed to meet potency and/or purity limits.
Your firm has since attributed the following out-of-limit potency results for released drug product lots tested between July, 2014 and July, 2015 to this issue:
• Lot # 14192051M, 10mcg/mL Fentanyl Citrate in 0.9% Sodium Chloride in 30mL BD Syringe, tested for potency at 7.78mcg/mL (limits ) (limits REDACTED (B)(4)). • Lot # 14192247M, 20mcg/mL Fentanyl Citrate in 0.9% Sodium Chloride in 30mL BD Syringe, tested for potency at 15.26mcg/mL (limits REDACTED (B)(4)). ...
Observation 2
Testing and release of drug product for distribution do not include appropriate laboratory determination of satisfactory conformance to the identity and strength of each active ingredient prior to release.
Specifically, your firm has not established a procedure for release testing of finished drug products that ensures each batch conforms at a minimum to limits for potency for each active ingredient before the batch is approved and released by your quality limit.
For example, your firm's Memphis, TN Center formulated a total of REDACTED (B)(4) batches of F entanyl Citrate drug products between August 20, 2014 and
July 13 2015. In accordance with your cur rent monitoring procedure for Potency and Purity, you r firm tested only REDACTED (B)(4) out of REDACTED (B)(4) batches.
Observation 3
Each batch of drug product purporting to be sterile and pyrogen-free is not laboratory tested to determine conformance to such requirements.
Specifically, your firm has not implemented a procedure requiring for every batch of finished drug product purporting to be sterile that Sterility testing be performed, or initiated if applicable, prior to the release. Also, your firm has not implemented a procedure requiring that each batch of finished drug product purporting to be non-pyrogenic is tested to show conformance to bacterial endotoxin limits prior to release.
• Document number CPS-775, “On-Going Sterility Monitoring Program,” effective AUG 04, 2015 Version 10.9 , section 5.2, establishes a sampling program fo r Sterility Moni toring that allows for a REDACTED (B)(4) number of batches to be tested based on a REDACTED (B)(4). It does not require Sterility testing for each individual batch.
• Bacterial endotoxin testing is not performed for any finished drug product batches.
Observation 4
Results of stability testing are not used in deter mining expiration dates .
Specifically, stability test results documenting a failure to meet product potency limits within the labeled product expiry date were not used to evaluate the appropriateness of current expiry dating for marketed drug products.
The following investigations of out-of-limit stability monitoring samples failed to include a documented evaluation of product expiry dating for all affected product lots represented in the study:
• HHE-15-017-R1 investigated the impact of a stability failure for 50mcg/mL Remifentanil in 0. 9% Sodium Chloride 2mL in 3mL REDACTED (B)(4) syringe, lot number 15132004C. The action
limits at expiry were REDACTED (B)(4) ; and your firm obtai
ned results for the three samples tested of 0.9 mcg/mL, 0.29 mcg/mL and 0.4 mcg/mL. The report concluded that REDACTED (B)(4) and the lot in question had expired on 6/8/2015.
• HHE-15-020 investigated the impact of a stability failure for 50mcg/mL Fentanyl Citrate Injection 100mL in 100mL Smiths Medical Cassette, lot number 150740034C. ...
Observation 5
Laboratory controls do not include the establishment of scientifically sound and appropriate specifications designed to assure that components and drug product containers and closures and drug products conform to appropriate standards of identity, strength, quality and purity.
Specifically, your firm has not established your own specifications for all incoming materials used in the formulation of finished drug products. Incoming materials include all approved finished human drug products, all critical product-contact components used in the compounding of sterile drug products, and all container-closure systems into which the compounded drug products are packaged.
Your firm has also not documented specifications for each of your formulated drug products purporting to be sterile to include at a minimum the identity and strength of each active ingredient, a limit for visible particles, sterility, and a limit for bacterial endotoxins.
Observation 6
Investigations of an unexplained discrepancy and a failure of a batch or any of its components to meet any of its specifications did not extend to other batches of the same drug product and other drug products that may have been associated with the specific failure or discrepancy.
Specifically, your fir m's historical trend reviews and impact evaluations documented for each investigation are deficient.
• Your firm's complaint handling procedure, document CPS-009, Version 8.0, effective SEP 25 2015 "Incident Complaint Handling Procedure," requires REDACTED (B)(4) and does not extend to other batches of the same drug product and other drug products that may have been associated with the specific failure or discrepancy.
• Forty-four (44) Health Hazard Evaluations (HHE) were performed by your firm between January 12, 2015 and November 25, 2015 to investigate confirmed out-of-limit test results, out-of-limit stability results, container/closure defects, product quality defects, and labeling discrepancies for released product batches. Your firm's HHEs which result in field corrections to remove or destro
y affected product do ...
State board of pharmacy records
No license with this exact name and city was found in the Illinois Department of Financial and Professional Regulation file dated Nov 13, 2026. A pharmacy can hold its license under a different legal name, so this is not a finding that it is unlicensed. Board file.
What this covers: Discipline IDFPR publishes with each license in the dataset (case number, action, start date and the department’s one-line reason), worded as the department gives it. The dataset marks 931 of these licenses as ever disciplined; some of them carry no action in the dataset. Actions in the data are dated May 23, 1980 to Sep 10, 2026.
This page restates FDA’s lists and state board of pharmacy records. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.
Sources
- FDA: Compounding: Inspections, Recalls, and other Actions
- FDA Registered Outsourcing Facilities (503B)
- FDA Data Dashboard: inspection classifications and published Form 483s
- FDA: FDA Form 483 Frequently Asked Questions
- Illinois Department of Financial and Professional Regulation license file
Records last pulled Nov 15, 2026. Every entry links to the original public record.